通威股份(600438.SH)半年度預盈28-30億元 同比增長177%-197%
格隆匯6月30日丨通威股份(600438.SH)公佈,預計2021年半年度實現歸屬於上市公司股東的淨利潤28-30億元,與上年同期相比將增加17.9-19.9億元,同比增長177%-197%;歸屬於上市公司股東的扣除非經常性損益的淨利潤28-30億元,與上年同期相比將增加18.41-20.41億元,同比增長192%-213%。
2021年上半年,公司各業務板塊經營穩健。其中,高純晶硅業務受益於下游需求的增長,產品供不應求,市場價格同比大幅提升,公司高純晶硅業務滿產滿銷,盈利實現大幅增長;在產業鏈供需不平衡的特殊情況下,公司電池片業務仍然保持了滿產滿銷,量利同比均實現較大幅度增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.